WSJ -- Daiichi Sankyo, the Tokyo-based pharmaceutical company, wanted to acquire a drug maker that specialized in generics after Japan eased its laws allowing sales of these cheaper versions of expensive drugs. Through the acquisition of Gurgaon-based Ranbaxy, Daiichi bought a mature firm that would help it access the American and Indian markets.
